Literature DB >> 32949147

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials.

Nima S Hejazi1,2, Mark J van der Laan3,4, Holly E Janes5,6,7, Peter B Gilbert5,6,7, David C Benkeser8.   

Abstract

The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success, effective vaccines to prevent many high-burden diseases, including human immunodeficiency virus (HIV), have been slow to develop. Vaccine development can be aided by the identification of immune response markers that serve as effective surrogates for clinically significant infection or disease endpoints. However, measuring immune response marker activity is often costly, which has motivated the usage of two-phase sampling for immune response evaluation in clinical trials of preventive vaccines. In such trials, the measurement of immunological markers is performed on a subset of trial participants, where enrollment in this second phase is potentially contingent on the observed study outcome and other participant-level information. We propose nonparametric methodology for efficiently estimating a counterfactual parameter that quantifies the impact of a given immune response marker on the subsequent probability of infection. Along the way, we fill in theoretical gaps pertaining to the asymptotic behavior of nonparametric efficient estimators in the context of two-phase sampling, including a multiple robustness property enjoyed by our estimators. Techniques for constructing confidence intervals and hypothesis tests are presented, and an open source software implementation of the methodology, the txshift R package, is introduced. We illustrate the proposed techniques using data from a recent preventive HIV vaccine efficacy trial.
© 2020 The International Biometric Society.

Entities:  

Keywords:  causal inference; stochastic interventions; targeted minimum loss estimation; two-phase sampling; vaccine efficacy

Mesh:

Substances:

Year:  2020        PMID: 32949147      PMCID: PMC8016405          DOI: 10.1111/biom.13375

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

1.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

2.  Collaborative double robust targeted maximum likelihood estimation.

Authors:  Mark J van der Laan; Susan Gruber
Journal:  Int J Biostat       Date:  2010-05-17       Impact factor: 0.968

3.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

4.  Estimation of the effect of interventions that modify the received treatment.

Authors:  S Haneuse; A Rotnitzky
Journal:  Stat Med       Date:  2013-08-02       Impact factor: 2.373

5.  Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Authors:  Holly E Janes; Kristen W Cohen; Nicole Frahm; Stephen C De Rosa; Brittany Sanchez; John Hural; Craig A Magaret; Shelly Karuna; Carter Bentley; Raphael Gottardo; Greg Finak; Douglas Grove; Mingchao Shen; Barney S Graham; Richard A Koup; Mark J Mulligan; Beryl Koblin; Susan P Buchbinder; Michael C Keefer; Elizabeth Adams; Chuka Anude; Lawrence Corey; Magdalena Sobieszczyk; Scott M Hammer; Peter B Gilbert; M Juliana McElrath
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

6.  Calibration weighted estimation of semiparametric transformation models for two-phase sampling.

Authors:  Youyi Fong; Peter Gilbert
Journal:  Stat Med       Date:  2015-02-04       Impact factor: 2.373

7.  A targeted maximum likelihood estimator for two-stage designs.

Authors:  Sherri Rose; Mark J van der Laan
Journal:  Int J Biostat       Date:  2011-03-11       Impact factor: 0.968

8.  A two stage design for the study of the relationship between a rare exposure and a rare disease.

Authors:  J E White
Journal:  Am J Epidemiol       Date:  1982-01       Impact factor: 4.897

9.  Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.

Authors:  Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani
Journal:  Vaccine       Date:  2016-02-10       Impact factor: 3.641

10.  Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Authors:  Youyi Fong; Xiaoying Shen; Vicki C Ashley; Aaron Deal; Kelly E Seaton; Chenchen Yu; Shannon P Grant; Guido Ferrari; Allan C deCamp; Robert T Bailer; Richard A Koup; David Montefiori; Barton F Haynes; Marcella Sarzotti-Kelsoe; Barney S Graham; Lindsay N Carpp; Scott M Hammer; Magda Sobieszczyk; Shelly Karuna; Edith Swann; Edwin DeJesus; Mark Mulligan; Ian Frank; Susan Buchbinder; Richard M Novak; M Juliana McElrath; Spyros Kalams; Michael Keefer; Nicole A Frahm; Holly E Janes; Peter B Gilbert; Georgia D Tomaras
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 7.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.